Solvonis Therapeutics PLC Ordinary Share (SVNS)

Industry Specialty Industrial Machinery

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.24p

Buy

0.26p

arrow-up0.015p (+6.25%)

Prices updated at 16 Dec 2025, 13:54 GMT

Prices minimum 15 mins delay

Prices in GBX

FTSE All-Share

-0.58%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Industrials

Industry

Specialty Industrial Machinery

Chairman

Mr. Dennis J. Purcell

CEO

Mr. Anthony Tennyson

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

3

Head office

Eccleston Yards

London

United Kingdom

SW1W 9NF

+44 7795430246

-

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Dennis J. Purcell Non-Executive Director, Chairman	-
Mr. Nicholas Christian Paul Nelson Non-Executive Director	-
Dr. Renata Crome Non-Executive Director	-
Mr. Anthony Tennyson Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
No data

Director dealings

Date chevron-l-regular chevron-r-regular	Action
27 May 2025	Purchase
27 May 2025	Transfer in
27 May 2025	Transfer in
16 May 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.